MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down

Merck reported strong Q3 2025 results, with adjusted EPS of $2.58, up 64% year-over-year, and revenues of $17.28 billion, both exceeding analyst estimates, driven by oncology, animal health, and new product launches. Despite the overall beat, sales for its key oncology drug, Keytruda, missed consensus, and HPV vaccine sales declined. The company narrowed its 2025 sales guidance to $64.5-$65.0 billion but raised its adjusted EPS forecast to $8.93-$8.98, reflecting benefits from acquisitions and deal revisions, partially offset by a one-time charge. Consequently, Merck's shares declined over 2% pre-market, primarily due to the Keytruda sales miss and the tightened revenue outlook.

Analysis

Merck (MRK) reported robust Q3 2025 results, with adjusted EPS of $2.58 beating estimates by 9.3% and revenues of $17.28 billion surpassing expectations, driven by oncology, new drugs like Winrevair, and the Animal Health segment. This led to a 64% year-over-year EPS increase and 4% revenue growth, excluding foreign exchange impacts.

However, flagship oncology drug Keytruda generated $8.14 billion, missing consensus estimates of $8.40 billion, which Merck attributed to channel movements. Additionally, Gardasil/Gardasil 9 sales plunged 25% due to reduced demand in China and Japan, while Januvia/Janumet saw 29% growth from U.S. pricing, partially offset by international generic competition.

The company narrowed its 2025 sales guidance to $64.5-$65.0 billion, reflecting a revised negative foreign exchange impact. Conversely, Merck raised its adjusted EPS forecast to $8.93-$8.98, citing benefits from a revised AstraZeneca deal, operational efficiencies, and a lower tax rate, despite acquisition costs and a $300 million one-time charge.

Despite the strong EPS beat, MRK shares declined over 2% pre-market, primarily due to the Keytruda sales miss and tightened revenue guidance. This reaction highlights investor sensitivity to key growth drivers and overall revenue trajectory, particularly given the stock's 12.9% year-to-date underperformance against the industry.

Key Decisions for Investors

• Investors should closely monitor Keytruda's sales performance in future quarters, as its underperformance relative to estimates was a key factor in the negative market reaction despite the overall EPS beat.
• Evaluate the long-term revenue contribution from new launches like Winrevair and Capvaxive, alongside the strategic benefits of the Verona Pharma acquisition, which are crucial for diversifying growth beyond Keytruda.
• Assess the revised 2025 guidance, weighing the positive EPS forecast, driven by operational improvements and tax benefits, against the narrowed sales outlook and one-time charges, which suggest potential near-term revenue headwinds.